News from and on Ebenbuild

In a new peer-reviewed study in Nature Communications Medicine, we demonstrate that Ebenbuild's lung digital twin quantitatively predicts where inhaled drugs deposit across the entire human lung. Built on patient-specific anatomy and physics-based simulation of airflow and aerosol transport, the model shows excellent agreement with 3D SPECT/CT imaging—turning the locally delivered dose from an assumption into a measurable quantity for inhaled drug and device development.

We are pleased to contribute to the Intertek Melbourn 4th Annual Inhaled & Nasal Biologics | DNA Forum (25–26 September 2025) with the presentation: "Breaking Barriers in IPF Treatment: In Silico Insights for Smarter Drug Delivery". Our session will highlight how Twinhale enables precise aerosol deposition modeling in disease-affected lungs, where conventional methods fall short. While IPF provides a clear use case, the same methodology applies to asthma, cystic fibrosis, COPD, and bronchiectasis - across nebulizers, pMDIs, DPIs, and SMIs.

Ebenbuild has published a landmark validation study in the Journal of Applied Physiology, demonstrating the accuracy of its digital twin lung technology. The study shows that the technology can precisely capture lung mechanics, even in severely damaged lungs. The work was conducted in collaboration with the University Clinic Schleswig-Holstein and researchers from the Technical University Munich. Using prospective clinical data, the team validated the predictive power of Ebenbuild’s model by comparing simulated lung deformation and aeration against electric impedance tomography (EIT) data from mechanically ventilated patients with Acute Respiratory Distress Syndrome (ARDS).

Our CEO Kei Wieland Müller will be joining 40 selected companies and 90+ investors at Europe's premier forum for Digital Health and MedTech.

Today we announce that Ebenbuild has received Euro 2.3 million funding under the European Innovation Council (EIC) Accelerator program to advance our digital twin platform technology

Our CTO Jonas Biehler gave a talk at a special event of the Bavarian Academy of Sciences and Humanities focusing on innovative technologies in medicine. He detailed how Ebenbuild's digital twin technology is improving regionally targeted drug delivery to the lungs and is en route to supporting clinicians in treating severe lung disease faster and better, from acute complications to chronic disease.

Ebenbuild has been selected as showcase company at the American Thoracic Society Respiratory Innovation Summit

New article about Ebenbuild in one of Germany's leading business papers.

We are excited to share that Ebenbuild’s Twinhale simulation technology played a key role in a newly published study in Nature Communications exploring the potential of inhaled PRS-220 for treating idiopathic pulmonary fibrosis.

Our CEO, Kei Wieland Müller, has been selected to present at the Live-Saving Innovations Stage and will be sharing insights into Ebenbuild’s lung digital twin platform technology and its cutting-edge application to personalizing mechanical ventilation for critically ill patients.

Ebenbuild has been accepted into the German Accelerator’s Life Sciences U.S. market access program, supported by the Federal Ministry for Economic Affairs and Energy. The program will help advance Ebenbuild’s digital lung twin technology in the U.S. by refining regulatory and market strategies with experienced U.S. experts, aiming to improve outcomes for patients with acute lung conditions like ARDS.

Today we are delighted to announce that industry veteran and renowned researcher Charles A. Taylor, PhD has been appointed Chairman of the Board. Charles is a founder of HeartFlow and a pioneer in the field of predictive, simulation-based medicine. His unparalleled expertise and excellent industry network of key opinion leaders, investors and healthcare companies will be invaluable as we work together to bring our products to the US healthcare system.

Ebenbuild featured prominently in the recently released annual report of BioM Biotech Cluster Development GmbH on Biotech in Bavaria! The article illustrates our quest to improve patient outcome in lung diseases using AI/physics-based digital twins.

A film crew from Hochschule München visited us to create an image video highlighting their Data Science & Scientific Computing study program and we couldn't be more thrilled with the result. At Ebenbuild, we are dedicated to pushing the boundaries of technology by creating digital twins of the lung, a groundbreaking approach that heavily relies on AI and simulation. It was an amazing opportunity to showcase how we leverage advanced data science techniques to innovate in the healthcare sector.

Ebenbuild joined key stakeholders from regulatory agencies and leading industry professionals at the 'FDA/Medical Device Innovation Consortium (MDIC) Symposium on Computational Modeling and Simulation' in Hyattsville, MD. We had a lot of fruitful discussions about our work, regulatory submissions involving computational modeling and simulation, and the required standards for model verification and validation.

We had the pleasure and honor to give the first lecute in the guest lecturer series of the Integrated Hospital Care Institute on 'Novel computational modeling enables a paradigm shift in healthcare -- towards innovative protective ventilation concepts in ARDS'. Scheduled around the lecture held by our co-founder Prof. Wolfgang A. Wall, he and our CEO Kei Wieland Müller had high-value conversations regarding medical, regulatory, technological, an product topics with the Hd. of Dept. of Outcomes Research Prof. Daniel Sessler, MD, Prof. Marcelo Gama de Abreu, MD, Direction MICU Eduardo Mireles-Cabodevila, MD, and Robert L. Chatburn, MHHS, RRT NPS, FAARC.

The start-up project 'BreatheAssist' from the Chair of Biophysics of the FAU Nürnberg-Erlangen successfully received funding from the 'Bundesministerium für Bildung und Forschung' for its project. Together with Ebenbuild, an interface between digital analysis software and innovative medical technology is to be developed.

Our Co-Founder and CTO Jonas Biehler is taking part at the Livetalk series of FORUM - Science & Health: ”Artificial intelligence is successfully used for diagnosis, prevention and personalised therapy. However, alongside the thriumphs there are challenges such as data protection, patent law, and the delicate balance between progress and ethical principles.“

We are happy to announce that we will be in Edinburgh at the Drug Delivery to the Lung Conference 2023. Also, our head of In Silico Trials, Maximilian Grill, is giving a talk about the output-steadiness of nebulizers with an aerosol storage chamber.

Our Head of In Silico Trials Maximilian Grill and CEO Kei Wieland Müller are giving an invited talk featuring our in silico models for drug delivery to the lung and the latest validation results of our AI/simulation technology.

We are delighted to announce that the German Federal Ministry of Education and Research has granted €1.8M for the research project Personalized Lung Twins for the Treatment of Acute Respiratory Distress Syndrome (UBIC) in collaboration with the University Hospital Schleswig-Holstein, University Hospital Augsburg, University Hospital Carl Gustav Carus Dresden, University Hospital RWTH Aachen and University Medical Center Mannheim.

We are happy to announce that Werner Boeing, former CIO of Roche Diagnostics and Multi-Board Member, has joined our Advisory Board. A passionate advocate and advisor for digital healthcare, Werner is a leader who embodies the attributes and experience to create successful technology and data-driven business models. With a career spanning more than thirty years across multiple industries, Werner has been involved in all phases and facets of business, particularly in the biotech and medtech sectors.

Ebenbuild is listed once more as one of the most promising AI-startups in Germany in the annual startup landscape by the appliedAI Institute

Our co-founders Kei and Jonas were guests on the Science4Life podcast to talk about digital twins, Ebenbuild's mission, and the future of healthcare.

We are pleased to announce that Charles Taylor, co-founder and CSO of Silicon Valley company HeartFlow, Inc., has joined our advisory board. Charles Taylor has led HeartFlow from the inception of its FFRct technology - a simulation-based assessment of coronary artery disease - to its recommendation in clinical guidelines in the US and UK. The lessons learned from his 15-year journey from a university spin-out to the development of a first-of-its-kind medical technology, while raising close to $800 million in the process, will be invaluable to us.

The Intel oneAPI program is aimed at startups that develop innovative software solutions for accelerated computing. We are excited to be able to participate in this program whose main mission is to empower startups!

Global University Venturing lists Ebenbuild among the twelve most exciting spin-outs worldwide!

We are happy to announce that we have joined the Open Source Image Consortium (OSIC) and are joining forces with them in the fight against idiopathic pulmonary fibrosis, fibrosing interstitial lung diseases, and other respiratory diseases.

Our CEO, Kei Müller, will present at the "Festival der Zukunft" by 1E9.

Changemakers in healthcare - How far can we push the boundaries, a fitting theme to present our vision at Bits&Pretzels HealthTech.

We proudly announce, that we have won the EIT Health Catapult competion in the digital health category.

Intel Ignite is Intel's highly selective program for deep-tech startups, helping them turn cutting-edge ideas into industry-disrupting technologies.

Today we are announcing our Seed round, led by Bayern Kapital GmbH and High-Tech Gründerfonds. This is a very big step for the whole team at Ebenbuild as the funding will enable us to expand our team and keep on working towards the goal to bring our digital twin technology to patients worldwide.

New article about Ebenbuild in one of Germany's leading business newspapers.

Ebenbuild recently partnered with Daylight for a UX-Design project. Take a look at their case study

Our R&D project BEATE is featured in the 2020 project gallery of the Federal Ministry of Education and Research

The latest cover story of the German magazine Bild der Wissenschaft is about ICUs and what it takes for physicians, nurses, and patients to win the fight for lives. Ebenbuild and our #digitaltwin technology are part of the feature

Ebenbuild is listed as one of the most promising AI-startups in Germany in the annual startup landscape by appliedAI Institute

DW did a feature with audEERING GmbH, mediaire, and Ebenbuild on how machine learning will advance diagnosis and patient care.

Nice analysis by t3n Magazin about startups - amongst others Ebenbuild - which bring digital technologies into hospitals to improve patient care.

Our digital twin is the cover story of the latest edition of the EHEALTHCOM magazine.

We are delighted to share that we have been listed among the top 50 startups in Germany.

Ebenbuild won 3rd place out of more than 150 national and international entries in Roche's Future X Healthcare Award. The award, initiated by Roche, aims to promote start-ups and young scientists who are making an important contribution to the digitization of healthcare and thus to the healthcare of tomorrow.

New article about our company in the specialist journal for out-of-hospital intensive care „Gepflegt Durchatmen“.

Ebenbuild won 4th place at the 2019 Science4Life Venture Cup, which is one of the largest competitions in the life science, chemistry and energy industry in Germany.

A short interview with our founders by the local startup magazine Munich Startup.

Ebenbuild was awarded as outstanding startup at the German contest „Gründerwettbewerb – Digitale Innovationen“. This contest is sponsored by the Federal Ministry of Economics and Technology and is one the most prestigious prizes for early stage startups in Germany. The ceremony took place at the days of digital innovation in Berlin